Microbiota medicine: towards a clinical revolution

After the last meeting of the International Society of Microbiota (ISM), a well-researched report and statement was published. Numerous researches have shown a two-way interaction between the intestinal microbiota and many organs of the human body such as the intestines, lungs, brain and skin. A large body of evidence demonstrated over a decade ago that microbial gut damage is a key factor in the pathogenesis of many local and systemic disorders. In this regard, a thorough understanding of the mechanisms involved in gut microbial symbiosis/dysbiosis is crucial for the clinical and health field.

The ISM Scientific Council has published the most recent studies on the involvement of the intestinal microbiota in the pathogenesis of many diseases. They also worked out the different strategies used to manipulate the gut microbiota in the prevention and treatment of disorders. The conclusion of this report confirms once again that the future of medicine and health is strongly linked to our microbiota.

21 top authors and members of the International Society of Microbiotafrom 8 countries and more than 10 reputable institutions published a new strategic report titled “Microbiota medicine: towards a clinical revolution”. Posted in the Journal of Translational Medicinethis mind-blowing review that covers everything you need to know about the microbiota.

From human microbiome and microbiota dysbiosis in human disease, to therapeutic strategies in manipulating the gut microbiota, this article clarifies the key role and implication of the microbiota in human health. The gut microbiota is constantly changing with human evolution, as well as with the host gastrointestinal microenvironment, making it easily altered by many endogenous and external factors. Among these is the microbiome of the built environment which can have a significant impact on human health.

It has been widely demonstrated that the gut microbiota is tightly linked to host organs through multidirectional crosstalk involved in the maintenance of global homeostasis. Among these flora-organ interactions: intestine-lung, intestine-brain, intestine-skin axes, and many others. Any microbial dysbiosis could lead to an increased risk of pathogenesis of many diseases. For example, some dysbioses are responsible for inflammation of the gastrointestinal tract, metabolic and cardiovascular-renal disorders, as well as neurological disorders.

In the therapeutic context, targeting specific microbial components or metabolites could provide a tool in the treatment of many diseases. Beyond pre- or probiotics, which are the traditional and first-line choice of microbial therapies, other strategies are being studied clinically such as FMT, metabolites, phages and miRNAs.

Prof. Marvin Edeascorresponding author and founder of ISM, Institut Cochin, INSERM, University of Paris, said “This is an excellent report which confirms that the future of medicine is strongly linked to the quality of our microbiota Targeting microbiota dysbiosis will be a huge challenge Another challenge we face today is targeting mitochondria and microbiota together. the Artificial intelligence will take microbiota medicine to an exceptional level where we will rapidly detect microbiota dysbiosis, modulate the microbiome and treat hundreds of diseases.”

You can read the full article in the BMC – Journal of Translational Medicine.

About the International Society for Microbiota (ISM):

The ISM was born in 2013 after the transformation of the Mitochondria-Microbiota Task Force into a larger group bringing together all the actors and experts working in the field of microbiota. The idea is to bring a new level of thinking and understanding of microbiota science out of the existing classical point of view. Gut and microbiota science is a dynamic, evolving field affected by multiple factors. ISM will bring this dynamic new perspective to accelerate the credible translation of this science into real consumer benefit. ISM also encourages communication and interaction between researchers, physicians, nutritionists, industrialists, food technology and strategic marketing managers through a global microbiota network, including at its annual global meeting. In 2022, the ISM is organizing its 9th world congress on targeting the microbiotafrom October 19 to 21, in Paris.

Warning: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.